RadioMedix and Curium's Detectnet PET diagnostic radiopharmaceutical copper-64 (Cu-64) DOTATATE has been included in the National Comprehensive Cancer Network (NCCN) guidelines.
It was added to the network's Clinical Practice Guidelines in Oncology -- Neuroendocrine and Adrenal Tumors, version 1.2021 for the evaluation of neuroendocrine tumors. Detectnet is a PET agent used to localize somatostatin receptor-positive neuroendocrine tumors in adults.